Androgen Deprivation Therapy for Prostate Cancer

In the monograph concerning hormonal treatment of prostate cancer special attention is paid to androgen deprivation therapy. Molecular, hormonal and cellular mechanisms of prostate cancer pathogenesis and progression are discussed. Results of animal research and clinical use of luteinizing hormone-releasing hormone (LHRH) agonists, antiandrogens and low dose of estrogens for androgen deprivation are described.

Autorentext

Sergiy O. Vozianov Corresponding Member of the National Academy of Medical Sciences of Ukraine, MD, DSc, Full Professor, Director of SI Institute of Urology of the NAMS of Ukraine .Bakhron T. Ishmuradov PhD, Teaching Assistant at the Department of Surgical Diseases 1, transplantology and urology of Samarkand State Medical University.